IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 9, 2019 · 10-Q · 40 days after period end · 0001564590-19-031260
| Metric | Q2 2019 | Q2 2018 |
|---|---|---|
| Net Income | -$9.06M | -$3.11M |
| EPS Diluted | -$0.57 | -$0.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end
